TRIP13 promotes tumor growth and is associated with poor prognosis in colorectal cancer
Colorectal cancer (CRC) is one of the most common neoplasms worldwide. However, the mechanisms underlying its development are still poorly understood. Thyroid hormone Receptor Interactor 13 (TRIP13) is a key mitosis regulator, and recent evidence has shown that it is an oncogene. Here, we report tha...
Gespeichert in:
| Veröffentlicht in: | Cell death & disease 2018-03, Vol.9 (3), p.402-14, Article 402 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 14 |
|---|---|
| container_issue | 3 |
| container_start_page | 402 |
| container_title | Cell death & disease |
| container_volume | 9 |
| creator | Sheng, Nengquan Yan, Li Wu, Kai You, Weiqiang Gong, Jianfeng Hu, Landian Tan, Gewen Chen, Hongqi Wang, Zhigang |
| description | Colorectal cancer (CRC) is one of the most common neoplasms worldwide. However, the mechanisms underlying its development are still poorly understood. Thyroid hormone Receptor Interactor 13 (TRIP13) is a key mitosis regulator, and recent evidence has shown that it is an oncogene. Here, we report that TRIP13, which is overexpressed in CRC, is correlated with the CEA (carcino-embryonic antigen), CA19-9 (carbohydrate antigen 19-9) and pTNM (pathologic primary tumor, lymph nodes, distant metastasis) classification. Multivariate analyses showed that TRIP13 might serve as an independent prognostic marker of CRC. We also found that TRIP13 promoted CRC cell proliferation, invasion and migration in vitro and subcutaneous tumor formation in vivo. Furthermore, the potential mechanism underlying these effects involves the interaction of TRIP13 with a 14-3-3 protein, YWHAZ, which mediates G2-M transition and epithelial-mesenchymal transition (EMT). Together, these findings suggest that TRIP13 may be a potential biomarker and therapeutic target for CRC. |
| doi_str_mv | 10.1038/s41419-018-0434-z |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5852242</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2014141531</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-2c1f19720c66f3a499813a894d2dcc5ba408d662e87a63f065404dadeb89cc1e3</originalsourceid><addsrcrecordid>eNp1kUtLAzEUhYMotlR_gBsJuHEzmtdMk40gxUehoIjiMqSZTDtlJqnJjMX-ejOMbzCbhJzvntybA8ARRmcYUX4eGGZYJAjzBDHKku0OGBLEcMI4F7s_zgNwGMIKxUUpImm2DwZEpAyNiRiC58eH6T2mcO1d7RoTYNPWzsOFd5tmCZXNYRmgCsHpUjUmh5syXq9dRGLFwroQ5dJC7SrnjW5UBbWy2vgDsFeoKpjDj30Enq6vHie3yezuZjq5nCWajVGTEI0LLMYE6SwrqGJCcEwVFywnudbpXDHE8ywjho9VRguUxb5ZrnIz50JrbOgIXPS-63Zem1wb23hVybUva-XfpFOl_K3YcikX7lWmPCWEkWhw-mHg3UtrQiPrMmhTVcoa1wZJEO4-OqU4oid_0JVrvY3jdZRgmSCko3BPae9C8Kb4agYj2SUn--RkTE52ycltrDn-OcVXxWdOESA9EKJkF8Z_P_2_6ztis6S-</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2019469221</pqid></control><display><type>article</type><title>TRIP13 promotes tumor growth and is associated with poor prognosis in colorectal cancer</title><source>Open Access: PubMed Central</source><source>Open Access: Nature Open Access</source><source>Springer Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>EZB Electronic Journals Library</source><creator>Sheng, Nengquan ; Yan, Li ; Wu, Kai ; You, Weiqiang ; Gong, Jianfeng ; Hu, Landian ; Tan, Gewen ; Chen, Hongqi ; Wang, Zhigang</creator><creatorcontrib>Sheng, Nengquan ; Yan, Li ; Wu, Kai ; You, Weiqiang ; Gong, Jianfeng ; Hu, Landian ; Tan, Gewen ; Chen, Hongqi ; Wang, Zhigang</creatorcontrib><description>Colorectal cancer (CRC) is one of the most common neoplasms worldwide. However, the mechanisms underlying its development are still poorly understood. Thyroid hormone Receptor Interactor 13 (TRIP13) is a key mitosis regulator, and recent evidence has shown that it is an oncogene. Here, we report that TRIP13, which is overexpressed in CRC, is correlated with the CEA (carcino-embryonic antigen), CA19-9 (carbohydrate antigen 19-9) and pTNM (pathologic primary tumor, lymph nodes, distant metastasis) classification. Multivariate analyses showed that TRIP13 might serve as an independent prognostic marker of CRC. We also found that TRIP13 promoted CRC cell proliferation, invasion and migration in vitro and subcutaneous tumor formation in vivo. Furthermore, the potential mechanism underlying these effects involves the interaction of TRIP13 with a 14-3-3 protein, YWHAZ, which mediates G2-M transition and epithelial-mesenchymal transition (EMT). Together, these findings suggest that TRIP13 may be a potential biomarker and therapeutic target for CRC.</description><identifier>ISSN: 2041-4889</identifier><identifier>EISSN: 2041-4889</identifier><identifier>DOI: 10.1038/s41419-018-0434-z</identifier><identifier>PMID: 29540729</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>13/2 ; 13/51 ; 14-3-3 protein ; 38 ; 42 ; 45 ; 64/60 ; 82/58 ; 82/75 ; 82/80 ; Antibodies ; Antigens ; Biochemistry ; Biomedical and Life Sciences ; Cell Biology ; Cell Culture ; Cell migration ; Cell proliferation ; Colorectal cancer ; Colorectal carcinoma ; Embryos ; Immunology ; Life Sciences ; Lymph nodes ; Mesenchyme ; Metastases ; Mitosis ; Therapeutic applications ; Thyroid</subject><ispartof>Cell death & disease, 2018-03, Vol.9 (3), p.402-14, Article 402</ispartof><rights>The Author(s) 2018</rights><rights>2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-2c1f19720c66f3a499813a894d2dcc5ba408d662e87a63f065404dadeb89cc1e3</citedby><cites>FETCH-LOGICAL-c470t-2c1f19720c66f3a499813a894d2dcc5ba408d662e87a63f065404dadeb89cc1e3</cites><orcidid>0000-0002-7280-2358 ; 0000-0002-1599-3725</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5852242/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5852242/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,41096,42165,51551,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29540729$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sheng, Nengquan</creatorcontrib><creatorcontrib>Yan, Li</creatorcontrib><creatorcontrib>Wu, Kai</creatorcontrib><creatorcontrib>You, Weiqiang</creatorcontrib><creatorcontrib>Gong, Jianfeng</creatorcontrib><creatorcontrib>Hu, Landian</creatorcontrib><creatorcontrib>Tan, Gewen</creatorcontrib><creatorcontrib>Chen, Hongqi</creatorcontrib><creatorcontrib>Wang, Zhigang</creatorcontrib><title>TRIP13 promotes tumor growth and is associated with poor prognosis in colorectal cancer</title><title>Cell death & disease</title><addtitle>Cell Death Dis</addtitle><addtitle>Cell Death Dis</addtitle><description>Colorectal cancer (CRC) is one of the most common neoplasms worldwide. However, the mechanisms underlying its development are still poorly understood. Thyroid hormone Receptor Interactor 13 (TRIP13) is a key mitosis regulator, and recent evidence has shown that it is an oncogene. Here, we report that TRIP13, which is overexpressed in CRC, is correlated with the CEA (carcino-embryonic antigen), CA19-9 (carbohydrate antigen 19-9) and pTNM (pathologic primary tumor, lymph nodes, distant metastasis) classification. Multivariate analyses showed that TRIP13 might serve as an independent prognostic marker of CRC. We also found that TRIP13 promoted CRC cell proliferation, invasion and migration in vitro and subcutaneous tumor formation in vivo. Furthermore, the potential mechanism underlying these effects involves the interaction of TRIP13 with a 14-3-3 protein, YWHAZ, which mediates G2-M transition and epithelial-mesenchymal transition (EMT). Together, these findings suggest that TRIP13 may be a potential biomarker and therapeutic target for CRC.</description><subject>13/2</subject><subject>13/51</subject><subject>14-3-3 protein</subject><subject>38</subject><subject>42</subject><subject>45</subject><subject>64/60</subject><subject>82/58</subject><subject>82/75</subject><subject>82/80</subject><subject>Antibodies</subject><subject>Antigens</subject><subject>Biochemistry</subject><subject>Biomedical and Life Sciences</subject><subject>Cell Biology</subject><subject>Cell Culture</subject><subject>Cell migration</subject><subject>Cell proliferation</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>Embryos</subject><subject>Immunology</subject><subject>Life Sciences</subject><subject>Lymph nodes</subject><subject>Mesenchyme</subject><subject>Metastases</subject><subject>Mitosis</subject><subject>Therapeutic applications</subject><subject>Thyroid</subject><issn>2041-4889</issn><issn>2041-4889</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kUtLAzEUhYMotlR_gBsJuHEzmtdMk40gxUehoIjiMqSZTDtlJqnJjMX-ejOMbzCbhJzvntybA8ARRmcYUX4eGGZYJAjzBDHKku0OGBLEcMI4F7s_zgNwGMIKxUUpImm2DwZEpAyNiRiC58eH6T2mcO1d7RoTYNPWzsOFd5tmCZXNYRmgCsHpUjUmh5syXq9dRGLFwroQ5dJC7SrnjW5UBbWy2vgDsFeoKpjDj30Enq6vHie3yezuZjq5nCWajVGTEI0LLMYE6SwrqGJCcEwVFywnudbpXDHE8ywjho9VRguUxb5ZrnIz50JrbOgIXPS-63Zem1wb23hVybUva-XfpFOl_K3YcikX7lWmPCWEkWhw-mHg3UtrQiPrMmhTVcoa1wZJEO4-OqU4oid_0JVrvY3jdZRgmSCko3BPae9C8Kb4agYj2SUn--RkTE52ycltrDn-OcVXxWdOESA9EKJkF8Z_P_2_6ztis6S-</recordid><startdate>20180314</startdate><enddate>20180314</enddate><creator>Sheng, Nengquan</creator><creator>Yan, Li</creator><creator>Wu, Kai</creator><creator>You, Weiqiang</creator><creator>Gong, Jianfeng</creator><creator>Hu, Landian</creator><creator>Tan, Gewen</creator><creator>Chen, Hongqi</creator><creator>Wang, Zhigang</creator><general>Nature Publishing Group UK</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7280-2358</orcidid><orcidid>https://orcid.org/0000-0002-1599-3725</orcidid></search><sort><creationdate>20180314</creationdate><title>TRIP13 promotes tumor growth and is associated with poor prognosis in colorectal cancer</title><author>Sheng, Nengquan ; Yan, Li ; Wu, Kai ; You, Weiqiang ; Gong, Jianfeng ; Hu, Landian ; Tan, Gewen ; Chen, Hongqi ; Wang, Zhigang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-2c1f19720c66f3a499813a894d2dcc5ba408d662e87a63f065404dadeb89cc1e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>13/2</topic><topic>13/51</topic><topic>14-3-3 protein</topic><topic>38</topic><topic>42</topic><topic>45</topic><topic>64/60</topic><topic>82/58</topic><topic>82/75</topic><topic>82/80</topic><topic>Antibodies</topic><topic>Antigens</topic><topic>Biochemistry</topic><topic>Biomedical and Life Sciences</topic><topic>Cell Biology</topic><topic>Cell Culture</topic><topic>Cell migration</topic><topic>Cell proliferation</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>Embryos</topic><topic>Immunology</topic><topic>Life Sciences</topic><topic>Lymph nodes</topic><topic>Mesenchyme</topic><topic>Metastases</topic><topic>Mitosis</topic><topic>Therapeutic applications</topic><topic>Thyroid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sheng, Nengquan</creatorcontrib><creatorcontrib>Yan, Li</creatorcontrib><creatorcontrib>Wu, Kai</creatorcontrib><creatorcontrib>You, Weiqiang</creatorcontrib><creatorcontrib>Gong, Jianfeng</creatorcontrib><creatorcontrib>Hu, Landian</creatorcontrib><creatorcontrib>Tan, Gewen</creatorcontrib><creatorcontrib>Chen, Hongqi</creatorcontrib><creatorcontrib>Wang, Zhigang</creatorcontrib><collection>Springer Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Science Journals</collection><collection>Biological Science Database</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cell death & disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sheng, Nengquan</au><au>Yan, Li</au><au>Wu, Kai</au><au>You, Weiqiang</au><au>Gong, Jianfeng</au><au>Hu, Landian</au><au>Tan, Gewen</au><au>Chen, Hongqi</au><au>Wang, Zhigang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>TRIP13 promotes tumor growth and is associated with poor prognosis in colorectal cancer</atitle><jtitle>Cell death & disease</jtitle><stitle>Cell Death Dis</stitle><addtitle>Cell Death Dis</addtitle><date>2018-03-14</date><risdate>2018</risdate><volume>9</volume><issue>3</issue><spage>402</spage><epage>14</epage><pages>402-14</pages><artnum>402</artnum><issn>2041-4889</issn><eissn>2041-4889</eissn><abstract>Colorectal cancer (CRC) is one of the most common neoplasms worldwide. However, the mechanisms underlying its development are still poorly understood. Thyroid hormone Receptor Interactor 13 (TRIP13) is a key mitosis regulator, and recent evidence has shown that it is an oncogene. Here, we report that TRIP13, which is overexpressed in CRC, is correlated with the CEA (carcino-embryonic antigen), CA19-9 (carbohydrate antigen 19-9) and pTNM (pathologic primary tumor, lymph nodes, distant metastasis) classification. Multivariate analyses showed that TRIP13 might serve as an independent prognostic marker of CRC. We also found that TRIP13 promoted CRC cell proliferation, invasion and migration in vitro and subcutaneous tumor formation in vivo. Furthermore, the potential mechanism underlying these effects involves the interaction of TRIP13 with a 14-3-3 protein, YWHAZ, which mediates G2-M transition and epithelial-mesenchymal transition (EMT). Together, these findings suggest that TRIP13 may be a potential biomarker and therapeutic target for CRC.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>29540729</pmid><doi>10.1038/s41419-018-0434-z</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0002-7280-2358</orcidid><orcidid>https://orcid.org/0000-0002-1599-3725</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2041-4889 |
| ispartof | Cell death & disease, 2018-03, Vol.9 (3), p.402-14, Article 402 |
| issn | 2041-4889 2041-4889 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5852242 |
| source | Open Access: PubMed Central; Open Access: Nature Open Access; Springer Open Access; DOAJ Directory of Open Access Journals; EZB Electronic Journals Library |
| subjects | 13/2 13/51 14-3-3 protein 38 42 45 64/60 82/58 82/75 82/80 Antibodies Antigens Biochemistry Biomedical and Life Sciences Cell Biology Cell Culture Cell migration Cell proliferation Colorectal cancer Colorectal carcinoma Embryos Immunology Life Sciences Lymph nodes Mesenchyme Metastases Mitosis Therapeutic applications Thyroid |
| title | TRIP13 promotes tumor growth and is associated with poor prognosis in colorectal cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T17%3A54%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=TRIP13%20promotes%20tumor%20growth%20and%20is%20associated%20with%20poor%20prognosis%20in%20colorectal%20cancer&rft.jtitle=Cell%20death%20&%20disease&rft.au=Sheng,%20Nengquan&rft.date=2018-03-14&rft.volume=9&rft.issue=3&rft.spage=402&rft.epage=14&rft.pages=402-14&rft.artnum=402&rft.issn=2041-4889&rft.eissn=2041-4889&rft_id=info:doi/10.1038/s41419-018-0434-z&rft_dat=%3Cproquest_pubme%3E2014141531%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2019469221&rft_id=info:pmid/29540729&rfr_iscdi=true |